Söndag 27 April | 05:52:38 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-12 08:30 Bokslutskommuniké 2025
2025-10-23 08:30 Kvartalsrapport 2025-Q3
2025-08-21 08:30 Kvartalsrapport 2025-Q2
2025-05-16 N/A X-dag ordinarie utdelning NANECH 0.00 SEK
2025-05-15 N/A Årsstämma
2025-04-30 08:30 Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-04-30 - Kvartalsrapport 2024-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
NanoEcho är verksamt inom sjukvården, med huvudsaklig fokus inom rektalcancerdiagnostik. Bolaget är verksamt i kliniskt skede, där man utvecklar en ny diagnostisk metod för att fastställa om tidig rektalcancer har spridit sig till närliggande lymfkörtlar. Metoden ämnar ge en korrekt diagnos och individanpassad behandling. NanoEcho grundades år 2013 och har sitt huvudkontor i Lund.
2023-02-03 08:30:00

NanoEcho is developing a system with the aim to offer the healthcare a more precise, simple, and cost-effective rectal cancer diagnosis. The prototype system used in the ongoing investigator-led clinical development studies has now been replaced with a system intended to meet market requirements. The first examination on surgically removed rectal cancer tissue with this system has now been performed.

In December, the detailed product development phase was completed. This resulted in a system developed with the aim to meet the market's requirements, including both the authorities' and customers' requirements. The product development phase has now moved into an integration and evaluation phase.

The integration work is proceeding according to plan. We assess that the new system's performance is adequate to replace the prototype system used in the ongoing clinical development studies. The first examination of surgically removed rectal cancer tissue has now been performed. We aim to increase the quality of collected clinical data and obtain valuable user information contributing into the evaluation of the system.

The fact that we have already replaced the prototype system with the new system in our investigator-led clinical development studies is the result of focused integration work carried out by our dedicated, experienced team. While we gather valuable feedback from the use of the system, we will continue with further integration work, comments CEO Linda Persson.